Skip to main content
. Author manuscript; available in PMC: 2018 May 1.
Published in final edited form as: Curr Opin Gastroenterol. 2017 May;33(3):149–157. doi: 10.1097/MOG.0000000000000352

Figure 2.

Figure 2

Therapies that are proposed to inhibit the transmigration of gut-derived lymphocytes into the hepatic environment in primary sclerosing cholangitis. In primary sclerosing cholangitis, mucosal vascular address in cell adhesion molecule 1 is aberrantly expressed. This allows aberrant binding and transmigration of gut-derived lymphocytes via α4β7 integrin. Binding and transmigration is further enhanced by vascular adhesion protein-1, which is constitutively present on hepatic endothelial cells and allows lymphocyte recruitment. CCR9–, chemokine receptor 9 inhibitor; MAdCAM-1, mucosal vascular addressin cell adhesion molecule 1; PSC, primary sclerosing cholangitis; VAP-1, vascular adhesion protein-1.